Home
About
Roadmap
Steering Committee
About ISTH
Blog
Topics
Basics of Hemophilia
Fundamental of Gene Therapies
Practical Considerations of Gene Therapies
Clinical Trial Efficacy and Safety
Patient Journey: Implementation to Lived Experience
Clinical Perspectives/Real-World Evidence
Roles of the Multidisciplinary Team
Recent Updates and Ongoing Efforts
Education
Resources Builder
Shared Decision Making
HTC Case Studies
EXPLORE Modules
Illustrated Clinical Trials
Interactive Webinars
Podcasts
Roadmap
Gene Therapy Resources
Conference Coverage
Microlearning
Monthly Roundup
News
Learning Tiers
Introductory
Intermediate
Advanced
Home
About
Roadmap
Steering Committee
About ISTH
Blog
Topics
Basics of Hemophilia
Fundamental of Gene Therapies
Practical Considerations of Gene Therapies
Clinical Trial Efficacy and Safety
Patient Journey: Implementation to Lived Experience
Clinical Perspectives/Real-World Evidence
Roles of the Multidisciplinary Team
Recent Updates and Ongoing Efforts
Education
Resources Builder
Shared Decision Making
HTC Case Studies
EXPLORE Modules
Illustrated Clinical Trials
Interactive Webinars
Podcasts
Roadmap
Gene Therapy Resources
Conference Coverage
Microlearning
Monthly Roundup
News
Learning Tiers
Introductory
Intermediate
Advanced
Home
About
Roadmap
Steering Committee
About ISTH
Blog
Topics
Basics of Hemophilia
Fundamental of Gene Therapies
Practical Considerations of Gene Therapies
Clinical Trial Efficacy and Safety
Patient Journey: Implementation to Lived Experience
Clinical Perspectives/Real-World Evidence
Roles of the Multidisciplinary Team
Recent Updates and Ongoing Efforts
Education
Resources Builder
Shared Decision Making
HTC Case Studies
EXPLORE Modules
Illustrated Clinical Trials
Interactive Webinars
Podcasts
Roadmap
Gene Therapy Resources
Conference Coverage
Microlearning
Monthly Roundup
News
Learning Tiers
Introductory
Intermediate
Advanced
WHAT ARE YOU LOOKING FOR?
Latest News
First Gene Therapy for Hemophilia B, CSL's HEMGENIX, Approved by the European Commission
20 February 2023
READ MORE
BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™️ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A
08 January 2023
READ MORE
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
29 December 2022
READ MORE
BioMarin Says FDA No Longer Plans Advisory Meeting for Roctavian
24 November 2022
READ MORE
FDA Approves First Gene Therapy to Treat Adults with Hemophilia B
23 November 2022
First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ Approved by European Commission (EC)
24 August 2022
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
24 June 2022
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
14 June 2022
PREV
9
10
11
12
13
14
15
16
17
18
NEXT
Back To Top
About
Contact Us
Term of Use
Privacy Policy
Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics
Home
About
Roadmap
Steering Committee
About ISTH
Blog
Topics
Basics of Hemophilia
Fundamental of Gene Therapies
Practical Considerations of Gene Therapies
Clinical Trial Efficacy and Safety
Patient Journey: Implementation to Lived Experience
Clinical Perspectives/Real-World Evidence
Roles of the Multidisciplinary Team
Recent Updates and Ongoing Efforts
Education
Resources Builder
Shared Decision Making
HTC Case Studies
EXPLORE Modules
Illustrated Clinical Trials
Interactive Webinars
Podcasts
Roadmap
Gene Therapy Resources
Conference Coverage
Microlearning
Monthly Roundup
News
Learning Tiers
Introductory
Intermediate
Advanced
Essential SSL
We use cookies to ensure that we give you the best experience on our website. Please review our
Terms of Use.
I accept